Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT2031200418
JPRN-jRCT2031200418
Completed
Phase 2

A phase 2a study of S-637880 in patients with neuropathic low back pain

agata - Tsutae0 sites51 target enrollmentMarch 12, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionseuropathic low back pain

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
europathic low back pain
Sponsor
agata - Tsutae
Enrollment
51
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

Since this study was prematurely terminated at all study sites, the efficacy and safety could not be fully evaluated.

Registry
who.int
Start Date
March 12, 2021
End Date
September 13, 2021
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
agata - Tsutae

Eligibility Criteria

Inclusion Criteria

  • •Patients who meet the following criteria:
  • •\- Patients with chronic pain located in the posterior aspect of the trunk and between the twelfth rib and the inferior end of the gluteal fold
  • •\- Patients whose average daily pain intensity are 4 or higher on Visit 1
  • •\- Patients whose weekly mean of average daily pain intensity are 4 or higher and less than 10 for 7 days including Visit 2 (Day 1\) on Visit 2

Exclusion Criteria

  • •Patients who are considered to have primary pain other than low back and leg pain or patients with neuropathic pain other than low back and leg pain

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Efficacy and safety of weekly nab-paclitaxel plus CBDCA in patients with CUPcancer of unknown primaryCUP, nab-Paclitaxel,CBDCA
JPRN-jRCTs051180084Yagi Toshinari17
Completed
Not Applicable
Phase I/II trial of S 81694 administered intravenously in;combination with paclitaxel to evaluate the safety,;pharmacokinetic and efficacy in metastatic breast cancermetastatic breast cancer10006291
NL-OMON46450Servier R&D Benelux18
Completed
Phase 2
A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta ThalassemiaBeta Thalassemiainherited blood disorder10038158
NL-OMON54921IMARA, Inc.15
Completed
Phase 2
A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome
NL-OMON48225Millendo Therapeutics SAS23
Completed
Not Applicable
Phase 1 Dose Escalation Study Assessing the Safety and Pharmacokinetics of PTC518 in Healthy Subjects
NL-OMON54972PTC Therapeutics, Inc.136